Novidin (Desmopressin Acetate)

Desmopressin acetate mimics the natural hormone vasopressin and selectively activates V2 receptors in the kidney’s collecting ducts. This activation raises cyclic AMP, causing aquaporin‑2 channels to move to the cell surface, which increases water reabsorption. The same receptor stimulation also triggers release of factor VIII and von Willebrand factor from endothelial cells.

The appropriate dose of Novidin is determined by the prescribing clinician based on the patient’s age, weight, renal function, and the specific indication. Dosage forms and strengths are selected to achieve the desired therapeutic effect while minimizing the risk of hyponatraemia or other adverse events.

Safety data for desmopressin acetate in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional after a thorough risk‑benefit assessment.

To request Novidin, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Novidin (desmopressin acetate) is a synthetic vasopressin analogue with high selectivity for V2 receptors, offering a longer half‑life and fewer vasoconstrictive effects than natural vasopressin. Compared with other antidiuretic agents, it provides more predictable water‑reabsorption and is also used to raise clotting factor levels, a benefit not shared by most diuretics or other ADH analogues.

Novidin should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and avoid storing it in areas with high humidity or extreme temperature fluctuations to maintain stability.

Novidin is administered orally, typically as a tablet or oral melt, depending on the formulation supplied. The patient should swallow the tablet with water, unless specific instructions advise otherwise, and follow the prescriber’s guidance on timing relative to meals and fluid intake.

The most serious risks include severe hyponatraemia, which can lead to seizures, cerebral oedema, or coma, and water intoxication. Patients should be monitored for rapid weight gain, confusion, or neurological symptoms, and fluid intake may need to be restricted under medical supervision.

Novidin is contraindicated in patients with known hypersensitivity to desmopressin acetate, uncontrolled hypertension, severe renal impairment, or those who have experienced severe hyponatraemia previously. It should also be avoided in individuals taking certain interacting medications without appropriate monitoring.